secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2025-03-24T23:59:59+00:00
Accession:  0001558370-25-003502
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences names Takeda veteran Adam Zaeske as CCO; Dierks steps down
------------------------------------------------------------------------------

- Jeffrey Dierks steps down as CCO effective March 31, 2025; receives $476,215 cash and accelerated vesting for 2025 awards.
- Adam Zaeske appointed as EVP and CCO effective March 31, 2025; previously Head of Central, South, and Eastern Europe at Takeda.
- Zaeske managed a $2B business across 25 countries with 900 employees; delivered 3 consecutive years of double-digit growth.
- Company reaffirms 2025 revenue guidance and states WAKIX is a $1B+ opportunity in adult narcolepsy alone.
- Zaeske brings 25 years of pharma experience, including rare disease and neurology launches.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025003502/0001558370-25-003502-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000155837025003502/hrmy-20250320x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-003502

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer